Published in Blood Weekly, March 17th, 2005
This drove the full-year gross margin earned on sales in 2004 to a record 48% of sales or $85.8 million, compared to $76.8 million or 44% of sales for 2003.
The higher margin on biopharmaceutical sales funded an unprecedented level of clinical and research achievement, including filing for licensure of three products in Europe: StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), PhosLo (calcium acetate) and Nabi-HB Intravenous [hepatitis B Immune Globulin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.